Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Lepodisiran in Healthy Participants
NCT04914546Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2021
- Primary completion
- Nov 2022
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of lepodisiran in Hyperlipoproteinemia a (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s). Started Jun 2021; status: completed.
02
Drugs
lepodisiran
03
Conditions
Hyperlipoproteinemia a
Beyond the preview
Go deeper on NCT04914546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914546.